openPR Logo
Press release

Bile Duct Cancer Treatment Market to Exceed US$ 312.3 Mn in 2025

Bile Duct Cancer Treatment Market to Exceed US$ 312.3 Mn in 2025

Cholangiocarcinoma, also known as bile duct cancer, is spreading widely in Southeast Asia, particularly in the Northeast region of Thailand. High consumption of raw fish in the Asia-Pacific (APAC) region is driving the incidence of liver fluke infections, thereby stimulating the occurrence of bile duct cancer. Increased industrialization is also attributing to the growth in the APAC bile duct cancer treatment market as exposure to harmful printing chemicals is high among industrial workers in countries such as China, Japan and India. Persistence Market Research’s new study on the global bile duct cancer treatment market reveals that by the end of 2025, APAC region will procure a global revenue share of over 45%.

Request for Table of Contents @ https://www.persistencemarketresearch.com/market-research/bile-duct-cancer-treatment-market/toc

In 2017, the global market for bile duct cancer treatments is anticipated to bring in revenues worth a little over US$ 168 Mn. Apart from rising incidence of bile duct cancer across the APAC and Middle East & Africa region, increasing healthcare spending is also expected to drive the demand for bile duct cancer treatments. Towards the end of 2025, the global bile duct cancer treatment market is projected to soar at a robust CAGR of 8%, raking in revenues worth US$ 312.3 Mn.

Bile Duct Cancer Treatment – Key Challenges

Request Report Multiple Chapter @ https://www.persistencemarketresearch.com/multiple-chapter/10094

The study has observed following factors as key hurdles hindering the overall expansion of global Cholangiocarcinoma treatment market : high costs of cancer treatment in the US. lack of awareness on causes of Cholangiocarcinoma in developing regions. regulatory agencies rebuffing approval of expensive drugs. unavailability of effective cancer care in APAC region. poor diagnosis rate and absence of clinical data

The study also reveals that ongoing trials for development of drugs on bile duct cancer treatment are creating newer pathways for improving the efficiency of treatment. Companies are exploring the clinical benefits of fusing new chemical entities in existing drugs on treatment of bile duct cancer. The key players in global bile duct cancer treatment market are also seeking regulatory approval of combination therapies for treatment of Cholangiocarcinoma. The study has recorded such developments while profiling the market’s leading participants, which include Pfizer, Inc., F. Hoffman-La Roche AG, Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, Novartis AG, Sanofi, Fresenius Kabi AG, Mylan N.V., Kyowa Hakko Kirin Co Ltd., Intercept Pharmaceuticals, Inc., Accord Healthcare Inc., Delcath Systems Inc., Celgene Corporation, and Johnson & Johnson.

For more information @ https://www.prnewswire.com/news-releases/global-cholangiocarcinoma-bile-duct-cancer-treatment-market-revenues-worth-us-3123-mn-by-2025---pmr-635374603.html

Key Excerpts from the Study

Treatment of bile duct cancer is presently achieved through combination therapies associated with chemotherapy. The study anticipates that by the end of forecast period, close to 70% of global bile duct cancer treatment revenues will be accounted by the Gemicitabine Combination Therapy.

Request to Sample of Report @  https://www.persistencemarketresearch.com/samples/10094

In 2017 and beyond, more than 85% of global market value will be attributed by extrahepatic Cholangiocarcinoma as a disease indicator.

The study also observes hospital pharmacies as largest distribution channel for bile duct cancer drugs, revenues from which are expected to reach nearly US$ 250 Mn by 2025-end.

The global market for Cholangiocarcinoma treatment is also witnessing dominance from external beam radiation therapy as these services are pegged to procure more than half of market’s value through 2025.

Get full report now @ https://www.persistencemarketresearch.com/checkout/10094

About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bile Duct Cancer Treatment Market to Exceed US$ 312.3 Mn in 2025 here

News-ID: 1032292 • Views:

More Releases from Persistence Market Research pvt ltd

Rise of Cloud Computing and Big Data Analytics Drives Processor Market Growth to US$ 332.0 billion by 2033
Rise of Cloud Computing and Big Data Analytics Drives Processor Market Growth to …
According to a recent report by Persistence Market Research, the global processor market is expected to reach a value of US$ 332.0 billion by 2033, growing at a CAGR of approximately 9.6% during the forecast period. The increasing demand for processors in smartphones, tablets, and other mobile devices is a key driver of market growth. The report also notes that the demand for processors in the automotive industry is expected
Building Products Market Expected to Grow at 5.2% CAGR to Reach USD 1.5 Trillion by 2026
Building Products Market Expected to Grow at 5.2% CAGR to Reach USD 1.5 Trillion …
the global building products market size was valued at USD 1.1 trillion and is expected to reach USD 1.5 trillion by 2026, growing at a CAGR of 5.2% during the forecast period. The building products market encompasses a wide range of products used in the construction and renovation of residential, commercial, and industrial buildings. These products include but are not limited to lumber and wood products, roofing materials, insulation, windows and
Road Sweeping Machine Market Size to Surpass US$ 5.9 billion by 2028 | Persistence Market Research
Road Sweeping Machine Market Size to Surpass US$ 5.9 billion by 2028 | Persisten …
Road Sweeping Machine Market The global road sweeping machine market is expected to reach a value of US$ 5.9 billion by 2028, growing at a CAGR of 6.5% from 2023 to 2028. The market growth is driven by several factors such as urbanization, increasing infrastructure development, rising awareness about environmental cleanliness, and government initiatives to promote sustainable living. Click Here to Get Free Sample Copy of this Report @https://www.persistencemarketresearch.com/samples/16750 Road sweeping machines are
Pigments & Dyes Market is expected to grow at a CAGR of 4.3% from 2023 to 2028
Pigments & Dyes Market is expected to grow at a CAGR of 4.3% from 2023 to 2028
Pigments & Dyes Market The global pigments and dyes market was valued at US$ 27.8 billion in 2022 and is expected to grow at a CAGR of 4.3% from 2022 to 2028, according to a report by PMR. The growth in the market can be attributed to the increasing demand for pigments and dyes from end-use industries such as textiles, paints, coatings, and plastics. The demand for high-performance pigments and dyes

All 5 Releases


More Releases for Cholangiocarcinoma

Cholangiocarcinoma Therapeutics Market New Era Of Industry and Forecast 2018-202 …
Global Cholangiocarcinoma Therapeutics Market: Overview Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known. Get Exclusive PDF Sample Copy Of This
Cholangiocarcinoma Therapeutics Market Dynamic Demand by 2028
Global Cholangiocarcinoma Therapeutics Market: Overview Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known. However, some of the factors
Cholangiocarcinoma Therapeutics Market Global Industry Trend Analysis and Foreca …
Global Cholangiocarcinoma Therapeutics Market: Overview Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known. However, some of the factors
Cholangiocarcinoma Therapeutics Market - Potential Opportunities & Key players 2 …
Global Cholangiocarcinoma Therapeutics Market: Overview Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known. Order Brochure for more detailed
Cholangiocarcinoma (Bile Duct Cancer) Treatment Market worth US$ 144.2 Million
In 2017, the global market for bile duct cancer treatments is anticipated to bring in revenues worth a little over US$ 168 Mn. Apart from rising incidence of bile duct cancer across the APAC and Middle East & Africa region, increasing healthcare spending is also expected to drive the demand for bile duct cancer treatments. Towards the end of 2025, the global bile duct cancer treatment market is projected to
Yeliva receives FDA orphan drug status for cholangiocarcinoma
US Food and Drug Administration has granted orphan drug designation to Yeliva a first-in-class, orally administered, sphingosine kinase-2 selective inhibitor with anticancer and anti-inflammatory activities, for the effective treatment of cholangiocarcinoma. The drug is developed by RedHill Biopharma. The investigation suggested that the drug is well endured and can be safely administered to patients suffering from the disease. The action of mechanism for Yeliva includes circulation in the patient’s body